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DMso induces drastic changes 
in human cellular processes and 
epigenetic landscape in vitro
M. Verheijen1, M. Lienhard  2, Y. schrooders1, o. Clayton3, R. Nudischer3, s. Boerno2, 
B. timmermann2, N. selevsek4, R. schlapbach4, H. Gmuender5, s. Gotta5, J. Geraedts6, 
R. Herwig2, J. Kleinjans1 & F. Caiment1
though clinical trials for medical applications of dimethyl sulfoxide (DMso) reported toxicity in the 
1960s, later, the FDA classified DMSO in the safest solvent category. DMSO became widely used in 
many biomedical fields and biological effects were overlooked. Meanwhile, biomedical science has 
evolved towards sensitive high-throughput techniques and new research areas, including epigenomics 
and microRNAs. Considering its wide use, especially for cryopreservation and in vitro assays, we 
evaluated biological effect of DMSO using these technological innovations. We exposed 3D cardiac 
and hepatic microtissues to medium with or without 0.1% DMSO and analyzed the transcriptome, 
proteome and DNA methylation profiles. In both tissue types, transcriptome analysis detected >2000 
differentially expressed genes affecting similar biological processes, thereby indicating consistent 
cross-organ actions of DMSO. Furthermore, microRNA analysis revealed large-scale deregulations of 
cardiac microRNAs and smaller, though still massive, effects in hepatic microtissues. Genome-wide 
methylation patterns also revealed tissue-specificity. While hepatic microtissues demonstrated non-
significant changes, findings from cardiac microtissues suggested disruption of DNA methylation 
mechanisms leading to genome-wide changes. The extreme changes in microRNAs and alterations in 
the epigenetic landscape indicate that DMSO is not inert. Its use should be reconsidered, especially for 
cryopreservation of embryos and oocytes, since it may impact embryonic development.
Dimethyl sulfoxide (DMSO) is an organic polar aprotic molecule with an amphipathic nature that is ideal for 
dissolving poorly soluble polar and non-polar molecules. DMSO is widely used as solvent in toxicology and 
pharmacology, for cryopreservation of cells, and as penetration enhancer during topological treatments. The use 
of DMSO is so obvious that applied concentrations are often unreported. DMSO is generally accepted as nontoxic 
below 10% (v/v) and, in practice, it is assumed that effects of DMSO are negligible1–3.
Research from the 1960’s till 1990’s pinpointed a lot of biologically relevant effects of DMSO. It was even 
actively investigated for medical use, but because of adverse effects especially affecting the eyes, most clinical trials 
were halted in 1965 by the United States Food and Drug Administration (FDA). At this point in time, DMSO was 
seen as extremely toxic, comparable to thalidomide4,5. The effects of DMSO differ depending on dose and route of 
administration. Introducing DMSO concentrations higher than 50% into the blood resulted in instant hemolysis, 
white cell stacking and fibrinogen precipitation while direct injection of DMSO intravenously could cause local 
irritation and necrosis6. LD50 values gained from monkeys indicated that 880 grams applied on the skin or 320 
grams injected intravenously would result in 50% mortality in 80 kg humans7. This relatively high dose changed 
the view on DMSO toxicity and the FDA classified DMSO in the same class as ethanol, namely class 3 solvent, 
which is the safest category with low toxic potential at levels normally accepted in pharmaceuticals8. This made 
the wide use of DMSO possible.
While generally used at relatively low concentrations, DMSO still has medically useful properties such 
as inducing anti-inflammation, nerve blockage (analgesia), diuretics, vasodilation and muscle relaxation9. 
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Furthermore, in cell biology, DMSO is also used as inducer of cell differentiation, free radical scavenger and 
radioprotectant, but most often for cryopreservation. Cell cultures for research are often stored in liquid nitrogen 
using slow cooling methodology. To prevent damage by intracellular ice crystals, cells are slowly cooled to −80 
degrees in the presence of 10% DMSO before storage in liquid nitrogen3. However, this procedure is insufficient 
for biomedical applications. Because slow cooling still induces damage due to extracellular ice crystals, cryopres-
ervation of human oocytes and embryos for in vitro fertilization (IVF) is accomplished by vitrification, in which 
higher concentrations of cryoprotectants are used to prevent ice formation not only in the cells, but in the entire 
solution. Higher concentrations are achieved by using mixtures (for example 15% DMSO in combination with 
15% ethylene glycol) which reduces the amount and toxicity of the individual cryoprotectants10. Furthermore, 
DMSO readily crosses most tissue membranes of lower animals and man9. For example, 2 hours after topological 
application, DMSO had penetrated all investigated hard and soft tissues (6 and 15 resp.) in rats11. DMSO is also 
able to enhance the permeability of other low molecular weight compounds, thereby making them pass mem-
branes or going deeper into a tissue as they normally would12, a property highly useful in topological therapies. In 
2009, the first to obtain FDA approval for topological DMSO usage was PENNSAID®, which contains diclofenac 
in a carrier with 45.5% DMSO13,14. This relatively high concentration of DMSO in topological applications is 
necessary because the skin is harder to penetrate than cell membranes.
Most insights into the molecular effects of DMSO were obtained last century often using high doses. In the 
meantime, biomedical science has evolved towards more sensitive high-throughput techniques and towards new 
areas of research, including epigenome modifications and microRNA-mediated gene silencing. Considering its 
wide use in many biological fields, we analyzed a relatively low dose of DMSO (0.1%, which is commonly applied 
in cell assays) to study the impact on the proteome, transcriptome and the epigenome. For this, we exposed in 
vitro 3D microtissues (a maturing iPSC-derived cardiac model and a mature hepatic model) to 0.1% DMSO and 
we collected samples in triplicate at 7 different time points during 2 weeks exposure (2 h, 8 h, 24 h, 72 h, 168 h, 
240 h and 336 h). Thereafter, DMSO effects were assessed with full transcriptome analysis (using ribo-depleted 
total RNA sequencing and microRNA sequencing), whole-genome methylation profiling (using MeDIP-seq) and 
proteomics analysis (using mass spectrometry). Our analysis clearly demonstrated that DMSO cannot be consid-
ered biologically inert but induces large alterations in microRNAs (miRNA) and epigenetic landscape, especially 
in the maturing cardiac model.
Results
Human 3D microtissues (MTs) of a maturing cardiac model and a mature hepatic model were exposed to cul-
ture medium with or without 0.1% DMSO for two weeks with sampling time points at 2, 8, 72, 168, 240 and 
336 hours. The proteome (approximately 2,000 measured proteins), the full transcriptome (including miRNAs) 
and whole-genome methylation were measured on material obtained from the same sample. Figure 1 contains a 
graphical overview of the experimental design. In order to obtain a first overview of DMSO-induced cross-omics 
effects, amounts of differentially changed entities (all corrected for multiple testing using FDR <0.05) are sum-
marized for each platform. Numbers of differentially changed entities differed between the tissue types, with 
cardiac samples showing a larger effect of DMSO than hepatic, with the exception of mRNAs. This difference is 
especially noticeable for miRNAs and genome methylation. Because proteomics data was least informative due to 
its partial nature, these results were included in Supplementary Data. Furthermore, principal component analysis 
(PCA), using averages of triplicates, for each platform (Fig. 2 & Supplementary Data) depicts clear differences 
between 0.1% DMSO exposed (DMSO) and untreated (UNTR) samples, with the exception of methylation in 
hepatic MTs.
To study the molecular effects of DMSO, affected cellular processes were analysed using the full transcrip-
tome. Thereafter, tissue-specific effects of DMSO on regulation of gene expression were investigated by analysing 
changes in miRNAs and genome-methylation.
Figure 1. Graphical overview of experimental design combined with summary of differential entities of 
each analysis method. Tissue-specific information is depicted in orange for cardiac and green for hepatic. 
Furthermore, exposures are coloured blue and measurement platforms purple. Abbreviations: h = hours; 
mRNA = messenger RNA; miRNA = microRNA.
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DMSO effects on cellular processes. DMSO effects on mRNAs were depicted by of PCA (Fig. 2a,b). 
The clear separation between UNTR and 0.1% DMSO indicated that DMSO was able to affect cellular processes 
by altering gene expression. Comparison between DMSO and UNTR resulted in 2051 differentially expressed 
genes (DEGs = FDR <0.05; of which 871 with |log2FC| >1) in cardiac MTs and 2711 DEGs (of which 1879 with 
|log2FC| >1) in hepatic MTs, of which 60.7% and 62.9% DEGs were downregulated respectively.
Pathway analysis of DEGs. To identify cellular processes affected by DMSO exposure, DEGs were used for path-
way overrepresentation analysis using ConsensusPathDB15 with the curated Reactome database16. Significantly 
overrepresented pathways (q-value < 0.05) were ordered using the hierarchical connections between (sub-) path-
ways obtained from the Reactome Pathway Browser (Supplementary Tables 1,2). A summary containing the 
Figure 2. PCAs depicting differences between DMSO and UNTR for all measured platforms. (a) PCA of RNAs 
indicates clear differences in RNA expression between DMSO (triangle) and UNTR (circles). Cardiac samples 
(left) are more distinct from UNTR than hepatic samples (right). (b) PCA of miRNAs reveals clear separation 
between DMSO and UNTR in cardiac samples, while hepatic samples seem more susceptible to the duration 
of the exposure (as seen by colour pattern that corresponds to the specific time points, see legend). (c) PCA of 
promotor methylation indicates differences between DMSO and UNTR for cardiac samples but not for hepatic 
samples.
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highest hierarchical pathway levels (from now on referred to as clusters) is included in Table 1 for cardiac and 
Table 2 for hepatic MTs.
Through pathway analysis on DEGs, 225 significantly overrepresented pathways (q-value < 0.05) were found 
in cardiac MTs, which corresponded to 19 clusters (out of a total of 25 clusters in the Pathway Browser), and 167 
pathways corresponding to 16 clusters in hepatic MTs. There was substantial overlap between the tissue types, 
with 60 pathways and 15 clusters found in both. Although there were differences in magnitude of DMSO effect 
between tissue types, the affected biological processes by DMSO do not appear to be tissue-specific.
The most significantly affected cluster by DMSO is the “metabolism” cluster in hepatic MTs. Here, most effects 
were found in pathways “citric acid cycle and respiratory electron transport” (q-value: 3.5 * 10−10, 63 DEGs 
out of 171 genes, 76.2% downregulated), “glucose metabolism” (q-value: 9.9 * 10−9, 36 DEGs out of 77 genes, 
80.5% downregulated) and “metabolism of lipids and lipoproteins” (q-value: 2.9 * 10−6, 165 DEGs out of 728 
genes, 55.2% downregulated). Changes in lipid and lipoprotein metabolism were not detected in cardiac MTs 
using DEGs, but similar effects of DMSO were observed for “citric acid cycle and respiratory electron transport” 
(q-value: 1.3 * 10−12, 58 DEGs out of 171 genes, 65.5% downregulated) and “glucose metabolism” (q-value: 2.8 
* 10−3, 20 DEGs out of 77 genes, 55.0% downregulated), though less genes were downregulated in cardiac MTs 
compared to hepatic MTs.
Another highly affected cluster by DMSO treatment in both tissue types was “vesicle-mediated transport”. 
DMSO effects in this cluster were mainly detected in processes related to Golgi-mediated protein transport and 
secretion. Of this process, “ER-to-Golgi anterograde transport” was the most affected (Cardiac: q-value: 2.4 * 10−6, 
38 DEGs out of 134 genes, 68.4% downregulated; Hepatic: q-value:1.0 * 10−5, 44 DEGs out of 134 genes, 44.4% 
downregulated). This pathway was also part of the cluster “metabolism of proteins”, which additionally revealed 
DMSO effects on “Asparagine N-linked glycosylation” (Cardiac: q-value: 2.1 * 10−6, 64 DEGs out of 283 genes, 
76.6% downregulated; Hepatic: q-value: 1.2 * 10−7, 83 DEGs out of 283 genes, 54.8% downregulated), which were 
post-transcriptional protein modifications necessary for transport of proteins from the ER to the Golgi17.
Though the cluster of “cellular responses to stress” was detected in both tissue types, overrepresented path-
ways differ. “Cellular senescence” was significantly affected in cardiac MTs (q-value: 2.6 * 10−4, pathway size: 192, 
42 DEGs, 64.3% downregulated), but not detected during pathway analysis in hepatic MTs. Finally, additional 
cardiac-specific clusters affected by DMSO were “cell cycle”, “DNA repair”, “organelle biogenesis and mainte-
nance”, but also the highly significant cluster (q < 0.01) of “chromatin organization”. Since the most significantly 
affected pathways were found in both tissue types, this indicates robust actions of DMSO.
DMSO effects observed in regulation of gene expression and translation. Pathways related to 
regulation of gene expression and translation were already detected during the pathway analysis of cardiac MTs 
(Table 3). Though these pathways were not overrepresented in hepatic MTs, the amounts of DEGs detected indi-
cated that DMSO was able to influence these processes and could induce biological alterations to the cell model.
Cluster name (stable identifier)
Set 
size
Ranking 
(DEGs)
Amount DEGs 
(%)
Amount DEGs 
(%)|log2FC| > 1 q-value
% DEGs Down-
regulated
Cellular responses to stress (R-HSA-2262752) 393 1 91 (23.5%) 28 (7.1%) 2.2E-09 61.5
Disease (R-HSA-1643685) 514 2 109 (21.5%) 33 (6.4%) 4.5E-09 61.5
Vesicle-mediated transport (R-HSA-5653656) 619 3 122 (20.0%) 48 (7.8%) 2.7E-08 55.7
Metabolism of proteins (R-HSA-392499) 1506 4 236 (16.0%) 80 (5.3%) 9.3E-07 68.2
Chromatin organization (R-HSA-4839726) 274 5 58 (21.3%) 19 (6.9%) 5.2E-05 53.4
Muscle contraction (R-HSA-397014) 198 6 41 (21.0%) 11 (5.6%) 9.5E-04 63.4
Gene Expression (R-HSA-74160) 1755 7 235 (13.7%) 76 (4.3%) 6.6E-03 55.7
Metabolism (R-HSA-1430728) 2035 8 269 (13.5%) 100 (4.9%) 7.9E-03 69.1
Extracellular matrix organization 
(R-HSA-1474244) 295 9 51 (17.6%) 23 (7.8%) 8.1E-03 52.9
Immune System (R-HSA-168256) 1950 10 257 (13.5%) 95 (4.9%) 9.7E-03 68.1
Cell Cycle (R-HSA-1640170) 551 11 85 (15.7%) 34 (6.2%) 1.0E-02 54.1
DNA Repair (R-HSA-73894) 323 12 54 (17.1%) 17 (5.3%) 1.1E-02 61.1
Organelle biogenesis and maintenance 
(R-HSA-1852241) 310 13 50 (16.5%) 20 (6.5%) 2.7E-02 66
Developmental Biology (R-HSA-1266738) 748 14 104 (14.1%) 33 (4.4%) 5.6E-02 57.7
Hemostasis (R-HSA-109582) 693 15 97 (14.2%) 36 (5.2%) 5.6E-02 68
Cell-Cell communication (R-HSA-1500931) 131 16 22 (17.1%) 7 (5.3%) 1.1E-01 68.2
Transport of small molecules (R-HSA-382551) 628 17 75 (12.1%) 28 (4.5%) 4.4E-01 65.3
Neuronal System (R-HSA-112316) 351 18 34 (9.8%) 13 (3.7%) 9.2E-01 47.1
Signal transduction (R-HSA-162582) 2538 19 260 (10.4%) 93 (3.7%) 9.9E-01 58.1
Table 1. Pathway analysis of Cardiac DEGs & DEPs detected after 0.1% DMSO exposure. Bold text: highly 
significant (cluster q < 0.01); Italic text: significant (cluster q < 0.05); text: cluster not significant, but contains 
significant (q < 0.05) sub-pathways. The stable identifiers displayed next to the cluster names can be used to 
retrieve the full pathway information from the Reactome database.
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DMSO effects observed in regulation by microRNAs. Tissue-specific influence of DMSO was observed in the 
sequencing data of miRNAs. Out of 1,105 sequenced cardiac miRNAs, 704 (=63.7%) were differentially expressed 
(DE, FDR <0.05) with 59.5% showing downregulation. Furthermore, the PCA plot (Fig. 2c) revealed a clear 
difference between the miRNAs of the treatment groups. In hepatic MTs, out of 1,033 sequenced miRNAs, 
186 (=18%) were DE with approximately half of the miRNAs being upregulated (47.3%). Furthermore, the 
PCA plot not only revealed a clear separation between miRNAs of the treatment groups, but indicated also a 
time-dependent effect. The two principal components (time and dose) represented together more than 95% of the 
total variation, leaving only minor effect for other factors.
To investigate the source of tissue-specific difference, gene expression changes in the process of miRNA bio-
genesis were investigated in more detail (Fig. 3). MiRNA biogenesis starts by the transcription of the primary 
miRNA transcribed by polymerase II (a complex of 11 subunits) or polymerase III (a complex of 10 subunits). 
In cardiac MTs, polymerase II contained 1 upregulated and 8 downregulated genes. In hepatic MTs, 5 genes were 
downregulated and 1 was upregulated. Though fewer genes were downregulated in hepatic MTs, the fold changes 
were larger compared to cardiac MTs. The cleavage of the pri-miRNA into pre-miRNA did not appear affected 
by DMSO exposure. DICER1 (which cleaves pre-miRNAs) was downregulated in cardiac MTs and upregulated 
in hepatic MTs, depicting a clear tissue-specific difference in the response to DMSO exposure. Finally, AGO2 
(encoding the main component of the miRNA-RISC) was downregulated in cardiac MTs. The changes in this 
process could induce differences in the cells miRNA content and therefore affect their regulatory function.
In cardiac MTs, the downregulated genes in miRNA biogenesis could explain the extremely high amount of 
downregulated DE miRNA and indicate extreme deregulation of gene silencing by miRNAs. In hepatic MTs, 
where the only significant change was the upregulation of DICER1 (Table 3), miRNA biogenesis was not dis-
rupted by DMSO exposure.
To get an indication of the DMSO effects on gene silencing by miRNAs, the miRTarBase database18, contain-
ing experimentally validated microRNA-target interactions (MTI), was used to obtain gene targets of detected 
DE miRNAs. We only included MTIs with strong evidence (validated by reporter assay, Western blot or qPCR). 
Of the 704 DE cardiac miRNAs, only 281 (=40%) could be found in the database, resulting in a total of 2051 gene 
targets potentially affected by DMSO-induced changes in miRNA gene silencing. For hepatic MTs, targets for 
Cluster name (stable identifier)
Set 
size
Ranking 
(DEGs)
Amount DEGs 
(%)
Amount DEGs 
(%)|log2FC| > 1 q-value
% DEGs Down-
regulated
Metabolism (R-HSA-1430728) 2035 1 472 (23.7%) 272 (13.4%) 9.1E-23 58.9
Vesicle-mediated transport(R-HSA-5653656) 619 2 164 (26.8%) 96 (15.5%) 4.8E-11 51.5
Extracellular matrix organization 
(R-HSA-1474244) 295 3 81 (28.0%) 55 (18.6%) 2.5E-06 77.8
Disease (R-HSA-1643685) 514 4 124 (24.5%) 77 (15.0%) 3.6E-06 61.3
Immune System (R-HSA-168256) 1950 5 371 (19.5%) 220 (11.3%) 1.0E-05 58.5
Muscle contraction (R-HSA-397014) 198 6 58 (29.7%) 40 (20.2%) 1.4E-05 82.8
Metabolism of proteins (R-HSA-392499) 1506 7 291 (19.7%) 176 (11.7%) 9.3E-05 59.9
Cellular responses to stress (R-HSA-2262752) 393 8 88 (22.7%) 59 (15.0%) 2.1E-03 69.3
Hemostasis(R-HSA-109582) 693 9 141 (20.6%) 88 (12.7%) 3.2E-03 56.7
Developmental Biology (R-HSA-1266738) 748 10 149 (20.2%) 85 (11.4%) 4.9E-03 69.1
Cell-Cell communication (R-HSA-1500931) 131 11 35 (27.1%) 21 (16.0%) 6.8E-03 62.9
Programmed Cell Death (R-HSA-5357801) 125 12 33 (26.8%) 15 (12.0%) 1.0E-02 54.5
Transport of small molecules (R-HSA-382551) 628 13 114 (18.4%) 75 (11.9%) 1.2E-01 58.8
Signal transduction (R-HSA-162582) 2538 14 377 (15.1%) 257 (10.1%) 8.5E-01 64.5
Neuronal system (R-HSA-112316) 351 15 44 (12.6%) 31 (8.8%) 9.8E-01 68.2
Gene expression (R-HSA-74160) 1755 16 239 (14.0%) 145 (8.3%) 1.0E + 0 55.6
Table 2. Pathway analysis of Hepatic DEGs & DEPs detected after 0.1% DMSO exposure. Bold text: highly 
significant (cluster q < 0.01); Italic text: significant (cluster q < 0.05); text: cluster not significant, but contains 
significant (q < 0.05) sub-pathways. The stable identifiers displayed next to the cluster names can be used to 
retrieve the full pathway information from the Reactome database.
Set 
size
Cardiac Hepatic
DEGs q-value
% DEGs down-
regulated DEGs q-value
% DEGs down-
regulated
Gene silencing by RNAs 134 35 (26.7%) 3.8E-05 74.3 25 (19.1%) 3.6E-01 72.0
Transcriptional regulation by small RNAs 108 32 (30.2%) 7.6E-06 75.0 24 (22.6%) 1.4E-01 75.0
MicroRNA biogenesis 13 5 (41.7%) 4.0E-02 60.0 1 (8.3%) 9.6E-01 0.0
Epigenetic regulation of gene expression 154 31 (20.5%) 6.8E-03 61.3 27 (17.9%) 4.5E-01 77.7
DNA methylation 68 18 (27.3%) 3.4E-03 66.6 13 (19.7%) 4.4E-01 92.3
Table 3. Pathways related to transcriptional regulation.
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106 DE miRNAs (=57%) were obtained, with a total of 545 potentially affected genes. The obtained gene targets 
were used to visualize overrepresented pathways using the Reactome Pathway Browser (Supplementary Fig. 3). 
Unexpectedly, overrepresented pathways were located in the same clusters for both tissue types. Most effects were 
observed for “Signal Transduction”, “Immune System” and “Gene Expression”. However, extreme deregulation of 
cardiac MTs and limited information about MTIs is making any downstream analysis on putative affected mRNA 
irrelevant.
DMSO effects observed in epigenetics. In order to assess epigenetic alterations introduced by DMSO, we focus 
on genome wide DNA methylation. Pathway analysis of cardiac gene expression revealed deregulation of DNA 
methylation pathways. Methyltransferases DNMT1, a key factor for maintenance of DNA methylation, and 
DNMT3A, facilitating both de novo and maintenance of DNA methylation, were upregulated while TET1, which 
plays a key role in active de-methylation, was downregulated in cardiac MTs (Fig. 4a). Upregulation of epige-
netic writers and downregulation of erasers after DMSO treatment pointed towards genomic hypermethylation, 
which potentially reduced transcriptional activity. In contrast, in hepatic pathway analysis, deregulation of DNA 
methylation was not observed. Note that, in both tissue types, transcriptional evidence for deregulation of other 
related epigenetic mechanisms were observed, such as histone methylation, where 16 genes and 13 genes were 
differentially expressed in cardiac and hepatic MTs respectively.
Whole genome methylation profiling by MeDIP-seq revealed 66,178 differentially methylated regions (DMRs; 
q-value < 0.05) in cardiac MTs. These alterations affected 1.1% of the covered genome. In line with the observed 
transcriptional changes of writers and erasers of DNA methylation, 71% of the DMRs corresponded to gain of 
methylation (46,984 hypermethylated regions vs 19,194 hypomethylated regions). In contrast, in hepatic MTs, no 
DMRs passed correction for multiple testing. Furthermore, the PCA plot (Fig. 2d) indicated a difference between 
treatment groups in cardiac MTs but not in hepatic MTs. Together, this illustrated tissue-specific impact of DMSO 
on the methylome in maturing cardiac MTs, while the mature hepatic MTs appeared unaffected.
In order to analyze the regulatory effects of the DMRs, the regions were annotated with known regulatory 
features, such as promoters, CpG Islands (CGIs), transcription factor binding sites (TFBS), and different classes 
of repetitive elements (Fig. 4b). Both hypo- and hypermethylated regions enriched specific repeat classes such as 
satellites (odds ratio of hyper/hypomethylation: 4.4/2.4) and simple repeats (hyper/hypomethylation 6.0/9.4 odds 
ratio), while repetitive elements in general were not enriched. The effect of DMSO on the upregulation of DNMTs 
and subsequent hypermethylation of repeat sequences was in line with previous findings in mouse embryoid 
bodies19. As expected, hypermethylated regions were also highly enriched in CGIs without regulatory evidence, 
e.g. not overlapping with TFBS and distal to transcription start sites. The odds ratio of these regions over the 
Figure 3. DMSO effect in the process of Gene silencing by RNAs. DEGs in biogenesis of miRNA. The complete 
process is divided in sub-processes (purple ovals) and depicting involved genes (blue rectangles) and detected 
DEGs for cardiac (orange rectangles) and hepatic (green rectangles) samples.
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genome was 5.5. While CGIs in general had an odds ratio of 3.2, there was no enrichment of CGIs overlapping 
known TFBS at promoters, the regions with the best studied regulatory potential. Just as promoter regions, other 
features such as exons, introns, and TFBS were affected by hypermethylation at approximately the odds of the 
captured genomic background (Fig. 4b). Although we found specific examples where promoter hypermethylation 
co-occurs with transcriptional repression, no global correlation between differential promoter methylation and 
gene expression was observed. Only 148 of the 1,436 genes (10.3%) featuring hypermethylated promoters were 
downregulated in DMSO treated cardiac MTs. 86 of the genes (6%) were overexpressed, contrary to the expected 
repressive effect of methylation.
Taken together, our data implied a fundamental influence of DMSO on DNA methylation in cardiac MTs, but 
not in hepatic MTs. The induced alterations affected preferentially satellites and simple repeats, as well as CGIs 
distal to promoters without known regulatory evidence. The expression of neighboring genes was not signifi-
cantly correlated to methylation differences. We therefore conclude that transcriptional repression by promoter 
hypermethylation was not the primary regulatory effect of the altered methylation marks, but the findings indi-
cate a global disruption of DNA methylation mechanisms.
Discussion
While high doses of DMSO were initially investigated for medical applications, lower doses are now commonly 
used as solvent for toxicology or for cryopreservation of cell cultures, oocytes and embryos. In the meantime, 
biological effects of DMSO have been forgotten or considered negligible. With the evolution of biomedical science 
towards more sensitive high-throughput techniques and towards new areas of research, including epigenome 
modifications and microRNA-mediated gene silencing, we evaluated the biological effects of DMSO exposure on 
the transcriptome and the epigenome.
The first overview of DMSO-induced cross-omics effects, observed through amounts of differentially changed 
entities and PCA analysis, indicated an increased susceptibility to DMSO effects in cardiac MTs. Differences 
between the investigated tissue types may relate to the fact that the cardiac model contains iPSC-derived human 
cardiomyocytes that are still maturing, while the hepatic model contains mature human hepatocytes. Currently, 
it is not yet possible for iPSC cells to reach an adult-like phenotype20,21 and the concise review on iPSC-derived 
human cardiomyocytes of Robertson et al.22 describes iPSCs to better resemble fetal cardiomyocytes (regarding 
structure, proliferation, metabolism and electrophysiology) rather than adult cardiomyocytes. Our observations 
of DMSO effects, notably the extreme epigenetics modifications in fetal-like cardiac cells, are particularly rele-
vant for cryopreservation during assisted reproductive technology (embryos, oocytes and sperm cells). Another 
Figure 4. Epigenetic regulation of gene expression. (a) DEGs involved in DNA methylation. The process is 
divided in sub-processes (purple ovals) and depicting involved genes (blue rectangles) and detected DEGs 
for cardiac (orange rectangles) and hepatic (green rectangles) samples. (b) Relative enrichment of DMRs 
(DMSO vs UNTR, FDR 5%) within genomic features. For each feature, the number of overlapping DMRs over 
the total number of tested windows for the respective feature is depicted. Compared to all genomic regions, 
hypermethylated regions are enriched for satellites, simple repeats, and CGIs distal to promoters without known 
regulatory evidence and hypomethylated regions are enriched for simple repeats.
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difference to be considered between our two cell models is the number of donors. Indeed, while the cardiac MTs 
are composed of IPSC-derived cardiomyocytes from a single donor (co-cultured with fibroblasts also from 1 
donor), hepatic MTs contain mature hepatocytes from 10 donors (co-cultured with Kupffer cells of 1 donor). 
While a single-donor model is more comparable to an in vivo situation then a multi-donor model, single-donor 
cardiac MTs might be more susceptible for bias due to genotype sensitivity than our multi-donor hepatic MTs that 
have the ability to even out these effects.
DMSO effects on cellular processes were analyzed using full transcriptome data. 2,051 DEGs were identified 
for cardiac MTs and 2711 DEGs for hepatic MTs. In both tissue types, downregulations are found for 60% of 
DEGs. Pathway overrepresentation analysis using DEGs, highlights similar DMSO effects in both tissue types. 
This indicates robust actions of DMSO that may possibly be extrapolated to other tissues. Observed changes in 
cellular processes include changes in mitochondrial pathways linked to ROS production and cellular ATP gen-
eration. DMSO is a known radical scavenger23. While this property of DMSO may provide protection against 
high levels of ROS, at normal or decreased levels of ROS, it may hamper basal cell metabolism by scavenging 
electrons needed for ATP production24. The resulting decrease in ATP content was observed in our two DMSO 
treated cell models (Supplementary Fig. 2). Cardiac MTs showed a steep decrease over time (87% decrease after 
2 weeks of exposure), while the ATP content of hepatic MTs show a small decrease initially (36% decrease in the 
first 72 h), after which ATP content slowly recovered to baseline level. Different downstream effects are relevant 
depending on the biological application of DMSO. For instance, for cell assays and toxicological research, changes 
in the amount of ROS or free energy in the cell impact on the capability of the cell to deal with induced stresses, 
thereby potentially leading to erroneous interpretation of results from in vitro assays. Within assisted reproduc-
tive technology, the ATP content is a good predictor of embryo viability. The DMSO-induced ATP decrease, 
especially in the cleavage-stage, can induce downstream effects that may disrupt cellular function, implantation 
ability and fetal development25,26. DMSO-induced reduction in implantation rates and pregnancy losses were 
already observed from animal models27.
Next to overlap in DMSO-affected processes between the tissue types, pathway analysis also revealed 
tissue-specific differences. The higher amount of affected processes detected in cardiac MTs may indicate 
increased susceptibility of cardiac MTs to the effects of DMSO, though there might also be a statistical bias due 
to different amount of DEGs used in the pathway analysis. The most significant difference is the detection of 
“chromatin organization” in cardiac MTs, while this cluster is not observed in hepatic MTs. Cardiac MTs also 
show more effects in other processes that regulate gene expression. Results of miRNA analysis revealed complete 
deregulation of cardiac miRNA biogenesis and miRNA content. Though changes in hepatic miRNA biogene-
sis were minimal, still 18% of detected miRNAs were significantly changed by DMSO exposure. Genome-wide 
methylation effects upon DMSO treatment show large tissue-specific variation. While there is no significant dif-
ference with respect to hepatic MTs, strong effects are observed with cardiac MTs, in particular with respect to 
specific repetitive sequences such as satellites and simple repeats. DNA repetitive elements account for 50% of 
the human genome and methylation in these regions suppresses their mobility and maintains genomic stability. 
Changes in the methylation status of repeats after DMSO treatment might destabilize the genome, implying 
phenotypic and pathological consequences. Indeed, recently, methylation changes of repetitive sequences, in 
particular satellite repeat elements, have been found in cardiomyopathic heart tissue compared to normal heart 
tissue28. Furthermore, it has been shown that DMSO changes genome-wide DNA methylation profiles dependent 
on specific gene loci. This may be due to drastic stimulation of DNMT1 and DNMT3. We observed upregulation 
of DNMTs, but literature also reported increased protein levels and catalytic activity by interaction of DMSO with 
their enzymes substrates (DNA and AdoMet)19,29,30. Furthermore, it is also possible that DMSO acts as a methyl 
donor to induce hypermethylation31. However, it has to be kept in mind that there is an interplay between DNA 
methylation and chromatin configuration, which is regulated by more processes than just DNMTs. Overall, we 
speculate the effects of DMSO on methylation changes to be a global deregulation characterized by a genome 
wide hypermethylation. Cell mechanisms in charge of removing detrimental methylations at important regions, 
such as TFBS, may then have removed the methylation changes with a negative outcome on cell survival, leav-
ing an over-representation of DMR in the repetitive elements. This is in analogy to mutation rates, which are 
higher for repetitive elements since they are less subjected to natural selection and DNA repair mechanisms32. 
We believe that the methylation difference between mature hepatic and maturing cardiac cells may be detri-
mental for cryopreserved cells and especially for oocytes and embryos. Previously reported DMSO effects on 
oocytes and embryos are limited to changes in gene expression in animal models27,33–36. We now showed, for the 
first time, the influence of DMSO on the epigenome of human cells in vitro. It is uncertain if exposed cells can 
recover from temporary DMSO exposures. Increased survival has been documented for embryos after with-
drawal from 2% DMSO for less than 24 h, though this was not the case with exposures longer then 48 h27. While 
methylation changes have an adaptive nature, they may also be persistent. From research conducted on the Dutch 
famine cohort, it is known that the periconceptional period (before conception until early pregnancy) is crucial 
for establishing and maintaining epigenetic marks. During this period epigenetic marks present on the paren-
tal DNA are removed to produce a totipotent zygote which is reprogrammed after implantation37. Exposures 
during this time may induce persistent epigenetic differences, which can result in disease later in life or pos-
sibly be inherited by the offspring to induce transgenerational effects38–42. It is already well known that infants 
conceived through assisted reproductive technologies are prone to be born preterm, have low birth weight and 
even have a significantly increased risk of birth defects43,44. Furthermore, some short-term health outcomes were 
slightly poorer in children conceived by IVF, though overall the outcomes were positive42,45. Regarding long-term 
health and development, though available data is limited, cardiovascular and metabolic risk factors that may 
ultimately result in chronic cardiometabolic disease have been indicated42. Furthermore, also epigenetic risks 
have been debated, mostly focusing on methylation and imprinting. For the most studied imprinting disorders 
Beck-with-Wiedemann syndrome and Angelman syndrome, the incidence was higher for children born after 
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assisted reproductive technologies compared to natural conception41,46–50. While there are many factors con-
tributing to these abnormalities, (decreased infertility, higher age of the parents, technical interference with a 
biological process, etc.) DMSO-induced effects may be one of them.
In the last decade, improvements made in artificial reproductive technology greatly increased the success rate 
of IVF treatments. Especially, improved cryopreservation techniques (transition to vitrification) aided greatly. 
Though not proven yet, increased success rates are reported when implanting previously frozen embryos51–53. 
This induced the “freeze all” trend in the clinic, which greatly increases the need for understanding consequences 
of cryopreservation at the molecular level. Furthermore, while storing frozen oocytes was initially intended 
for women threatened by decreased fertility due to disease, in our carrier-focused society, it has also become a 
method to prevent age-related infertility for women who want to delay motherhood54. The most recent develop-
ment in assisted reproductive technology is the emerging of concerns about DMSO effects. While there is still 
controversy on this topic, the field is moving towards DMSO-free methods. However, DMSO-free does not auto-
matically mean safe because of the use of other cryoprotectants55–57.
Conclusions
Our study highlights the capability of DMSO to induce changes in cellular processes in both cardiac and hepatic 
cells, but more severely, induce alterations in miRNA and epigenetic landscape in the 3D maturing cardiac model. 
The changes in cellular processes can have consequences for conclusions drawn from cell assays and therefore 
also in any application of these findings (e.g. false negative drug toxicity conclusions). Furthermore, the extreme 
changes in miRNA and alterations in the epigenetic landscape may pose a threat, especially for assisted reproduc-
tive technology. Genome-wide hypermethylation induced by global deregulation of methylation mechanisms, 
especially when it affects genes important in development, may have negative consequences directly, later in life 
or possibly in later generations.
Overall, use of DMSO should be avoided where possible. However, for the time being, DMSO is indispensable 
within biotechnological applications. In these cases, the effects that DMSO may have should be considered and 
the concentration should be kept as low as possible, because even at low concentrations DMSO is not inert.
Methods
samples. In this study, 3D InSightTM Human Cardiac Microtissues (InSphero, for beta-testers) were used, 
containing a co-culture of approximately 4000 iPSC-derived human cardiomyocytes from a female Caucasian 
donor with no known disease phenotype and 1000 cardiac fibroblasts from an 18 year old Caucasian male. The 
MTs were cultured in 3D InsightTM Human Cardiac Microtissue Maintenance Medium (InSphero). Furthermore, 
3D InSightTM Human Liver Microtissues (InSphero) were used, approximately 1000 primary human hepatocytes 
(multi-donor pool of 5 males and 5 females between 7–59 years old) in co-culture with 1000 primary human 
Kupffer cells from a Caucasian 27 year old of unreported gender. The MTs were cultured in 3D InsightTM Human 
Liver Microtissue Maintenance Medium- AF (InSphero).
exposure. The microtissues (MTs) were exposed to medium only (=untreated) or medium containing 0.1% 
DMSO for two weeks. Medium was changed three times daily, in concordance with the experimental design of 
our current research58. During the 2 week exposure, there were a total of 7 sampling time points at 2, 8, 24, 72, 
168, 240 and 336 hours, which were sampled in triplicate (total 21 samples per condition). Per sample, 36 cardiac 
MTs or 54 hepatic MTs were used in order to obtain sufficient amounts of RNA for sequencing.
RNA sequencing sample preparation. Total RNA was isolated using the AllPrep DNA/RNA/miRNA 
Universal Kit (Qiagen). The sample was depleted of ribosomal RNA using the Ribo-Zero Gold rRNA Removal 
kit (Human/Mouse/Rat) (Illumina®) and prepared for sequencing with the SENSE total RNA library preparation 
kit (Lexogen). After library preparation, the quality was assessed on Agilent 4200 TapeStation and library con-
centration was determined by QubitTM before sequencing (paired-end 100 bp) on the HiSeq2000. Two files per 
sample were obtained, split in left and right reads, and Lexogen adapter sequences (first 12 bases of all reads) were 
removed using Trimmomatic59 (v.0.33). The quality of the sequencing data was checked using FastQC60 (v.0.10.1) 
before and after trimming. For cardiac samples, no samples were discarded because of poor quality. Two samples 
were discarded because of low read counts (UNTR_002_3 and UNTR_240_3) and principal component analysis 
(Supplementary Fig. 1) revealed 4 outliers which were removed (UNTR_008_3, UNTR_168_2, UNTR_240_2 
and DMSO_336_2). Finally, because only one replicate of 240 hour untreated samples remained, all samples of 
this time point were removed from statistical analysis. For hepatic samples, no samples were discarded.
RNA data-analysis. Read counts for genes were obtained by aligning the reads to the reference genome 
(Genome Reference Consortium Human Build 38, GRCh38.p7) using RSEM61 (v.1.2.28) with the paired-end and 
Bowtie262 (v.2.2.6) option. Thereafter, the read counts for each gene were used for determination of differentially 
expressed genes using the DESeq263 R package (v.1.16.1). Here, the design was set according to exposure (UNTR 
or DMSO), other settings were kept to their default parameters, except for minimum count, which was set to an 
average read count of one across all samples. Finally, remaining ribosomal genes were filtered out of the dataset to 
ensure complete ribosomal depletion of the data.
MiRNA sequencing sample preparation. An aliquot of the isolated total RNA was selected on size and 
ligated using the TruSeq Small RNA Library Prep Kit (Illumina®). After library preparation, the samples were 
sequenced (paired-end 100 bp) on the HiSeq2000. Adapter sequences were trimmed64 and reads between 16 and 
35 bp were kept for analysis. Three samples were discarded because of low read counts (Cardiac: UNTR_168_1, 
UNTR_168_2 and Hepatic: DMSO_002_3). Furthermore, principal component analysis (Supplementary Fig. 1) 
revealed no outliers.
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MiRNA data-analysis. MiRNA data analysis was done similarly as described previously65, except for the 
use of mirDeep2, which does not gain additional information when using human samples. In short, PatMaN66 
(v.1.2.2) was used to align trimmed reads to the human genome without allowing mismatches or gaps. To obtain 
complete read counts for 3’ and 5’ miRNA species, the mapping output was parsed.
proteomics. Proteomics data was also obtained and analyzed. Methods and results are included in 
Supplementary data.
MeDIP sequencing. For preparation of MeDIP-Seq libraries, the low input MeDIP protocol67 was modi-
fied. DNA was fragmented to 100–200 bp using the Covaris S2 system. Because of lower DNA yield for cardiac 
0.1% DMSO samples, the triplicates were pooled before fragmentation. End repair and A tailing was performed 
using the NEBNext® UltraTM library prep kit for Illumina® (NEB), adapters were ligated with NEBNext® UltraTM 
Ligation Module (NEB) and samples were purified using Agencourt® AMPure® XP beads (Beckman Coulter). 
Methylated fragments were captured using the MagMeDIP kit (Diagenode). In short, denatured DNA was mixed 
with anti-5-meC-antibody and captured using magnetic beads. Capture efficiency was determined by qPCR 
against spiked-in Lambda-DNA fragments in precapture and postcapture library samples. Libraries were ampli-
fied in a final PCR step using barcoded TruSeq primers. Quality was assessed on Agilent Bioanalyzer 2100 and 
library concentration was determined by QubitTM and qPCR.
MeDIP data-analysis. In order to gain exhaustive genome-wide coverage the triplicate samples that have 
been sequenced individually were merged before alignment. MeDIP sequencing reads were aligned to the 
GRCh38 reference genome using bwa Version 0.7.15-r114068, and analyzed in 250 base windows using the R/
bioconductor package QSEA69 (v.1.4.0) with standard parameters. Within QSEA, the MeDIP enrichment was cal-
ibrated with 450k methylation array measurements of primary hepatocytes (GSM999339) and cardiac myocytes 
(HCM, GSM999381) from ENCODE70, for the hepatic and cardiac micro tissues respectively. To this end, beta 
values of the calibration samples were computed with the R/bioconductor package Minfi71 (v.1.24.0), genomic 
locations of the array probes were mapped from GRCh37 to GRCh38 using the UCSC liftOver command line 
tool72, and probes within 250 base windows were averaged. Differentially methylated regions obtained from 
QSEA were annotated with gene, exon, and promoter (transcription start site +/− 2 kilobases) information from 
RefSeq, ENCODE TFBS and model based CpG islands, all obtained via the UCSC table browser. Since ENCODE 
TFBS were not available for GRCh38, genomic locations were mapped from GRCh37 using the liftOver tool.
Data Availability
The datasets generated and analyzed during the current study are available in the BioStudies database (http://www.ebi.
ac.uk/biostudies) under accession numbers S-HECA1, S-HECA5, S-HECA9, S-HECA18, S-HECA33, S-HECA34, 
S-HECA47, S-HECA139, S-HECA158, S-HECA361, S-HECA401, S-HECA403.
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